Pancreatic adenocarcinoma

This trial is testing a personalized vaccine made from unique proteins (neoantigens) found in a person's tumor. The goal is to see if the vaccine is safe and can help slow or stop cancer growth in people with solid tumors, including pancreatic cancer. About 136 participants with …

This phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for controlling metastatic pancreatic cancer in people with inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the…

Researchers are testing whether adding two drugs to standard chemotherapy can shrink tumors and extend life in people with metastatic pancreatic cancer. Participants receive gemcitabine and nab-paclitaxel (standard chemo), plus cemiplimab (an immunotherapy approved for skin cance…

This trial is testing whether giving a single dose of radiation directly to the tumor area during surgery is safe for people with localized pancreatic cancer. Participants first receive standard chemotherapy and stereotactic body radiation therapy (SBRT), then at the time of surg…

This early-phase study tests a two-part approach for people with advanced pancreatic cancer. First, a special scan identifies cancer cells. Then, a targeted radioactive treatment is given to destroy those cells. The goal is to check safety and find the right dose in 30 participan…

This study tests whether adding two experimental drugs (elraglusib and losartan) to standard chemotherapy (FOLFIRINOX) can prevent metastatic pancreatic cancer from becoming resistant to treatment. About 70 adults with untreated, advanced pancreatic cancer will receive the combin…

This phase II trial is testing whether adding the drug veliparib to standard chemotherapy (gemcitabine and cisplatin) can shrink tumors or slow cancer growth in people with advanced pancreatic cancer who have BRCA1, BRCA2, or PALB2 gene mutations. The study has two parts: one com…

This phase 2 trial tests a combination of two drugs, atezolizumab and cabozantinib, in 30 people with metastatic pancreatic cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. Researchers will al…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This trial tests a procedure called High-Intensity Focused Ultrasound (HIFU) for people with pancreatic cancer that cannot be removed by surgery. The study has two parts: first, checking how safe the procedure is, and second, seeing if it helps patients live longer. About 26 part…

This early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and look at side effects. Researchers also…

This early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…

This phase III trial tests whether giving chemotherapy before and after surgery (perioperative) works better than giving it only after surgery (adjuvant) for people with pancreatic cancer that can be removed. The study involves 358 participants and uses a combination of four chem…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…

This study is testing a combination of two chemotherapy drugs (gemcitabine and nab-paclitaxel) with a precise type of radiation called proton therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the highest safe dose of…

This phase II trial is testing a combination of two experimental drugs (AZD0171 and durvalumab) plus standard chemotherapy in 126 people with advanced pancreatic cancer. The goal is to see if the combo is safe and helps patients live longer. Participants must have metastatic dise…

This phase 2 trial tests whether adding the experimental drug Ampligen to standard care can help people with locally advanced pancreatic cancer that hasn't spread. About 90 participants who have completed at least four months of initial chemotherapy will receive either Ampligen p…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This study is testing whether changing the timing of two chemotherapy drugs, gemcitabine and nab-paclitaxel, can improve tumor shrinkage in people with pancreatic cancer that has spread to other organs. About 67 participants will receive the drugs on an optimized schedule. The go…

This early-phase trial is testing whether an experimental oral drug called BXCL701 can change how the immune system responds to pancreatic cancer. The study will enroll people with untreated, locally advanced or metastatic pancreatic cancer who can undergo tumor biopsies before a…

This phase II trial tests an adaptive chemotherapy approach for people with pancreatic cancer that can be removed by surgery. The goal is to see if adjusting the chemo regimen based on early response can increase the number of patients who become eligible for surgery. About 32 pa…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This phase 2 trial is testing the safety and effectiveness of glipizide, a standard diabetes drug, for lowering blood sugar in people with pancreatic cancer. The study includes 29 participants with active pancreatic cancer and high blood sugar. Researchers will measure blood suga…

This phase 1 trial tests a combination of the chemotherapy drug gemcitabine and the targeted drug elimusertib in people with advanced pancreatic, ovarian, or other solid tumors that have spread. The goal is to find the safest dose and see whether the combination can shrink or sta…

This study tests a drug called tisotumab vedotin, alone or with other cancer medicines, in people with advanced colorectal, lung, pancreatic, or head and neck cancers that have stopped responding to standard treatments. About 350 participants receive different dosing schedules to…

This early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy with immunotherapy drugs and standard chemo to see if it's safe and what dose works best. About 74 a…

This study compares two radiation methods given before surgery for pancreatic cancer that can be removed. About 102 participants will receive either standard radiation with chemo or a more targeted radiation (SBRT). The goal is to see which approach better controls the cancer and…

This early study tests whether combining two drugs, pembrolizumab (Keytruda) and lenvatinib, can help control advanced pancreatic cancer that has already been treated. Fifteen participants will receive the combination to see if it shrinks tumors. The goal is to gather initial dat…

This study tests whether delivering a chemotherapy drug called floxuridine directly to the liver through a surgically placed pump can better control tumors that have spread from pancreatic cancer. Participants also receive standard chemotherapy. The goal is to see if this combina…

This study tests whether adding zolbetuximab to standard chemotherapy helps people with metastatic pancreatic cancer live longer. Zolbetuximab targets a protein (CLDN18.2) found in most pancreatic tumors, helping the immune system attack the cancer. About 393 adults whose cancer …

This early-phase trial tests a new approach for people with advanced pancreatic or ovarian cancer that has not responded to standard treatments. Participants receive a single infusion of their own immune cells, engineered to recognize and attack cancer cells (huCART-meso), along …

This early-phase trial is testing whether combining the targeted drug olaparib, the immunotherapy durvalumab, and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. The study enrolls 18 participants who have already rec…

This trial tests whether adding an experimental drug called AMP945 to standard chemotherapy (nab-paclitaxel and gemcitabine) can improve tumor shrinkage in people with advanced pancreatic cancer that cannot be removed by surgery. The study has two parts: first, finding the best d…

This phase II trial compares two chemotherapy regimens in 176 older patients with metastatic pancreatic cancer. One group receives gemcitabine plus nab-paclitaxel, the other receives fluorouracil, leucovorin, and liposomal irinotecan. The goal is to see which combination helps pa…

This phase II trial is testing two different drug combinations for people with metastatic pancreatic cancer that has spread. One group gets a standard chemo plus S-1 and leucovorin; the other gets standard chemo plus oxaliplatin. The goal is to see which combo works better at shr…

This phase 2 trial tests whether adding galeterone to standard chemotherapy (gemcitabine) can shrink tumors or slow disease in people with advanced pancreatic cancer that has not responded to prior treatments. The study enrolls about 15 adults with metastatic disease who have alr…

This study compares a new three-drug combination (NABPLAGEM) against a standard two-drug chemo regimen for people with advanced pancreatic cancer that has spread and carries a BRCA or PALB2 gene mutation. The trial enrolls 10 participants whose cancer worsened after initial treat…

This early-phase trial is testing whether adding an experimental drug called IM156 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with advanced pancreatic cancer. The study involves 19 participants and is being run by M.D. Anderson Canc…

This study tests a new combination for people with pancreatic cancer that cannot be surgically removed or has spread. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab), alongside standard chemotherapy. The goal is to see i…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This study tests whether combining three immunotherapy drugs (domvanalimab, zimberelimab, and APX005M) can safely control metastatic pancreatic cancer. The trial enrolls 46 people whose cancer has spread and standard treatments have stopped working. Researchers will monitor side …

This phase 3 trial tests a new drug called daraxonrasib (RMC-6236) against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug o…

This early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…

This early-stage trial is testing a new drug called anvumetostat, given together with other standard chemotherapy drugs, for people with advanced cancers of the digestive system (stomach, bile ducts, or pancreas) that have a specific genetic change called MTAP deletion. The main …

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This early-phase trial tests a new approach for people with pancreatic cancer that cannot be removed right away. Tiny nanoparticles called NBTXR3 are injected directly into the tumor and then activated by radiation therapy. The goal is to find a safe dose and see if this combinat…

This early-phase trial tests a new type of radiation called pulsed low-dose-rate (PLDR) for people with pancreatic cancer that cannot be removed right away. The radiation is given in small, spaced-out bursts along with the chemotherapy drug gemcitabine. The goal is to see if this…

This early-phase study tests a new treatment called EGFR-BATs for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are trained in a lab to better attack cancer cells. The main goal is …

This study tests whether giving chemotherapy both before and after surgery helps people with pancreatic cancer live longer compared to chemotherapy only after surgery. About 378 patients with resectable pancreatic cancer will be randomly assigned to one of two treatment schedules…

This Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…

This study tests a new treatment called Saltikva, a weakened Salmonella bacteria that carries a human immune-boosting gene (IL-2), in people with metastatic pancreatic cancer. Participants take Saltikva by mouth along with standard chemotherapy. The goal is to see if adding Salti…

This early-phase trial tests a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy and an immunotherapy drug (nivolumab), for people whose pancreatic cancer was removed by surgery. The goal is to see if the vaccine can be made successf…

This study tests whether adding a drug called defactinib to targeted radiation therapy can help control advanced pancreatic cancer better than radiation alone. About 42 people with inoperable pancreatic cancer will take part. The goal is to see if the combination slows cancer gro…

This phase 2 trial tests a new drug called ZN-c3 combined with the chemotherapy gemcitabine in 12 people with advanced pancreatic cancer that has worsened after platinum-based treatment. The goal is to see if the combination is safe and can slow cancer growth. Participants take Z…

This study tests a new drug called narmafotinib, taken as a daily pill, together with a standard chemotherapy regimen (mFOLFIRINOX) in people whose pancreatic cancer has spread. The trial has two parts: first, finding a safe dose, then comparing two doses in 20 people each. The g…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (mFOLFIRINOX) before surgery is safe and tolerable for people with pancreatic cancer that can be removed. About 20 adults with resectable or borderline resectable pancreatic cancer will rec…

This phase 2 trial tests whether giving a higher-than-standard dose of radiation, along with chemotherapy, can shrink pancreatic tumors enough to make them removable by surgery. The study includes 47 people with locally advanced pancreatic cancer that currently cannot be surgical…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This early-phase study tests a new type of radiation therapy (SCART) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the highest safe dose that can destroy the tumor while protecting nearby organs. About 24 participants wi…

This phase 2 trial tests whether a precise, high-dose radiation technique called SBRT can lower the chance of cancer coming back in the pancreas area after surgery. The study involves 50 adults with pancreatic cancer who had surgery and are at high risk of recurrence. They will r…

This early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is sa…

This early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This study tests a combination of two chemotherapy drugs and two immunotherapy drugs given before surgery to people with pancreatic cancer that can be removed. The goal is to shrink the tumor and help the immune system fight the cancer, potentially improving outcomes. The trial i…

This study compares two approaches to prevent pancreatic leaks after Whipple surgery: giving antibiotics for a short time with a drug called octreotide versus giving antibiotics for a longer time. About 103 adults at intermediate or high risk for leaks will take part. The goal is…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…

This phase II trial is testing a combination of liposomal irinotecan (Onivyde) and FOLFOX chemotherapy given before surgery to people with pancreatic cancer that can be removed. The study includes 45 adults with early-stage disease. The goal is to see if this approach is safe and…

This study tests whether taking pancreatic enzymes (Pertzye) with meals can help people with metastatic pancreatic cancer maintain their body weight during chemotherapy. The trial includes 17 participants who are starting a standard chemo regimen called FOLFIRINOX. Researchers wi…

This phase 2 trial tests whether adding tiny radioactive beads (OncoSil™) directly into the tumor can improve outcomes for people with locally advanced pancreatic cancer that cannot be removed by surgery. About 88 participants will receive either standard FOLFIRINOX chemotherapy …

This study tests a drug called nimotuzumab combined with radiation and chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can better control the tumor for at least a year. The trial will enroll 30 part…

This early-phase trial is testing whether adding the diabetes drug metformin and a specific dietary supplement (including curcumin, vitamins, and other natural compounds) to standard chemotherapy (gemcitabine and abraxane) is safe and feasible for people with pancreatic cancer th…

This study tests stereotactic body radiotherapy (SBRT), a precise, high-dose radiation given over 2 weeks, for people with high-risk localized pancreatic cancer. The goal is to see if it can stop the tumor from growing locally for at least 12 months. The trial includes 30 partici…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This study tests whether adding a high-dose pancreatic enzyme replacement (Pancreaze) to standard care can help patients with advanced pancreatic cancer who have weight loss and trouble digesting food. About 36 adults will take the enzymes with meals and snacks for 8 weeks. The g…

This program offers expanded access to NanoPac, a cancer treatment, for people with advanced pancreatic, prostate, or lung cancer who cannot join ongoing clinical trials. The goal is to provide the drug to those who have no other options. However, the program is no longer availab…

This study tests a new drug called DZ-002 in adults with metastatic pancreatic cancer that has been stabilized with initial chemotherapy. The goal is to find the best dose and see if it is safe and can help keep the cancer from growing. Participants receive weekly IV infusions of…

This phase II trial tests whether switching from one chemotherapy regimen to another early on, before surgery, can help remove pancreatic cancer more completely. It includes patients with resectable, borderline resectable, or locally advanced unresectable pancreatic cancer. The s…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This program gives adults with locally advanced pancreatic cancer access to a device that delivers gentle electric fields to the abdomen, combined with standard chemotherapy. The goal is to see if this approach is safe and feasible while the device awaits FDA approval. Participan…

This phase II/III trial compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combo (nab-paclitaxel plus gemcitabine) in people with metastatic pancreatic cancer that has BRCA1, BRCA2, or PALB2 gene mutations. T…

This study tests a two-step treatment for people with pancreatic cancer that hasn't spread but can't be removed by surgery. First, patients receive a stronger chemotherapy cocktail (modified FOLFIRINOX), followed by precise, high-dose radiation (SBRT). The goal is to see if this …

This study tests whether adding the experimental drug ivaltinostat to standard chemotherapy (capecitabine) can help keep metastatic pancreatic cancer from worsening. About 70 adults whose cancer did not progress on initial treatment will receive either the combination or capecita…

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. It is for people with advanced pancreatic cancer that cannot be removed by surgery. The main goals are to see if the procedure is safe and possible to do. About 37 participant…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study looks at whether giving chemotherapy first can shrink pancreatic tumors that have grown into nearby arteries, making them safe to remove with surgery. Researchers want to see if this approach can completely remove the cancer without leaving any behind. Only 2 people ar…

This trial tests a new approach for people with advanced cancers that have a specific genetic change called KRAS G12V. Patients receive their own immune cells that have been genetically modified to recognize and attack the cancer. They also get chemotherapy and an immunotherapy d…

This phase 1 trial tests a combination of radiation therapy and the chemotherapy drug Abraxane (nab-paclitaxel) in people with pancreatic cancer that cannot be surgically removed. The goal is to find the safest and most effective doses to improve local tumor control and survival.…

This study looks at whether switching between two chemotherapy drugs (FOLFOX and FOLFIRI) can reduce side effects in people aged 65 and older with metastatic pancreatic cancer. The goal is to find a treatment that is easier to tolerate than the standard three-drug regimen. 37 par…

This early-stage study tests a new drug called zolbetuximab combined with standard chemotherapy for people with a specific type of advanced pancreatic cancer. The drug targets a protein on cancer cells to help the immune system attack the tumor. The main goals are to check safety…

This study tests whether adding the immunotherapy drug durvalumab to focused radiation (SABR) can help people with locally advanced pancreatic cancer. The goal is to shrink tumors enough to allow surgery. The trial includes 18 participants who have already received standard chemo…

This study tests a new drug called ABTL0812 added to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has spread. The goal is to see if the combination is safe and works better than chemo alone. The trial was suspended, so res…

This study tests whether adding losartan (a blood pressure drug) and nivolumab (an immunotherapy) to standard chemotherapy and radiation can improve surgery outcomes for people with localized pancreatic cancer. About 168 participants with borderline resectable or locally advanced…

This early-phase trial tests whether adding a targeted drug called ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer that has a specific gene mutation (IDH1) will receive the drug combination fo…

This study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aim…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This pilot study is testing whether routine MRI scans can find early signs of pancreatic cancer in people who carry BRCA, ATM, or PALB2 gene mutations, which raise their risk. About 250 participants will undergo MRI, MRCP, endoscopic ultrasound, and provide blood, tissue, and sal…

This trial is testing a new, noninvasive method called LINFU® that uses low-intensity ultrasound to stimulate the pancreas, helping to collect pancreatic juice for analysis. The goal is to see if this approach can detect early, asymptomatic pancreatic cancer and precancerous lesi…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study aims to develop a blood test that predicts how well a patient's advanced pancreatic cancer will respond to different chemotherapy regimens. Researchers will analyze circulating tumor cells (CTCs) from 74 participants to see if the test can identify the most effective t…

This study is testing a computer model called PRISM that uses electronic health records to predict who might develop pancreatic cancer. Researchers will analyze data from over 6 million people aged 40 and older across 44 US healthcare centers. The goal is to see if the model can …

This study tests a new radioactive tracer called 18F-alphavbeta6-binding-peptide to see if it can safely and clearly show cancers in the breast, colon, lung, or pancreas. About 27 adults with these cancers will get the tracer and have a PET scan. The goal is to find out if this m…

This study tests a program of exercise, protein drinks, and mind-body activities like yoga for people aged 65 and older with advanced ovarian or pancreatic cancer. The goal is to see if patients can stick with the program while on chemotherapy before surgery. The study is small, …

This study tests whether a supervised, video-based exercise program done at home during chemotherapy can help people with pancreatic cancer get stronger before surgery. About 58 patients will take part. The goal is to see if the program is safe and helps improve recovery.

This study looks at whether acupuncture can help manage pain after open abdominal surgery for colorectal or pancreatic cancer. About 70 patients will either receive acupuncture or standard care. The goal is to see if acupuncture reduces pain and the need for opioid painkillers, h…

This study looks at whether screening for malnutrition and providing weekly nutritional support can improve quality of life for people with pancreatic cancer that cannot be removed by surgery. About 100 adults with this type of cancer are taking part. The goal is to see if better…

This study tests whether a supervised, at-home resistance training program using a tablet is safe and helpful for people with advanced pancreatic cancer or those recovering from surgery. About 25 participants will do guided exercises during chemotherapy or after surgery. The goal…

This study aimed to see if a food supplement called ARACOMPLEX® could help maintain quality of life in patients with advanced pancreatic cancer receiving chemotherapy. The supplement contains maca extract, vitamins, and minerals. However, the trial was withdrawn before enrolling …

This study tests whether starting palliative care early—right after diagnosis—improves quality of life for people with advanced pancreatic cancer. 250 participants receive regular visits from a palliative care team, plus referrals to exercise and nutrition experts. The goal is to…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study tests two different drug combinations in people with advanced colorectal, pancreatic, or leiomyosarcoma cancers that have not responded to standard treatments. Participants receive either olaparib plus durvalumab or cediranib plus durvalumab. The main goal is to unders…

This pilot study at Mayo Clinic tests whether personalized education and genetic counseling can increase genetic testing in people with a first-degree relative who had pancreatic cancer. About 50 participants will receive tailored information and counseling. The goal is to see if…

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…

This study was designed to test new drug combinations for people with pancreatic cancer that hasn't spread. It planned to compare new treatments against standard chemotherapy in three groups based on how far the cancer had grown. However, the study was withdrawn before enrolling …

This study is collecting saliva, stool, blood, bile, and tumor samples from 200 people undergoing surgery for pancreatic or related cancers. Researchers want to see if the types of bacteria in these samples can help predict who will have complications after surgery and how the ca…

This study looks at whether a blood test (ctDNA) can find tiny amounts of cancer left behind after pancreatic cancer surgery. Researchers will follow 150 patients who had surgery and chemotherapy to see if the test predicts who will have a relapse. The goal is to improve early de…

This study looks at a protein called DCAMKL-1, which may be a stem cell marker in pancreatic cancer. Researchers want to see how its levels change before and after treatment in 60 patients. The goal is to understand how current therapies affect this marker, not to test a new trea…

This study explores whether a special PET-MRI scan using a tracer called FAZA can safely measure oxygen levels (hypoxia) in pancreatic tumors. About 20 adults with advanced, non-spreading pancreatic cancer will get two scans—before and after standard radiation. The goal is to see…

This study looks at whether analyzing CT scans with a computer technique called radiomics can predict which patients with advanced pancreatic cancer will not respond to chemotherapy. Researchers will study 400 patients and track survival over time. The goal is to find early signs…

This study follows 500 adults with pancreatic cancer who had surgery intended to remove all visible cancer. Researchers want to learn how often the cancer returns within the first year, where it shows up (like the liver or lungs), and how it is detected. Participants receive stan…

This study looks at whether a specific surgical technique (called peri-adventitial dissection) can help surgeons remove all cancer cells during pancreatic cancer surgery. The trial involves 102 adults with non-spreading pancreatic tumors who are having a standard operation called…